iRadimed
IRMD
214 hedge funds and large institutions have $750M invested in iRadimed in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 98 increasing their positions, 61 reducing their positions, and 30 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 61
1.73% more ownership
Funds ownership: 59.69% → 61.42% (+1.7%)
2% more capital invested
Capital invested by funds: $734M → $750M (+$15.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 228 → 214 (-14)
18% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.58M
37% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$11.7M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.8M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$7.47M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$6.72M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTCM
Nine Ten Capital Management
Chicago,
Illinois
|
-$7.1M |
| 2 |
SG Americas Securities
New York
|
-$5.84M |
| 3 |
Jane Street
New York
|
-$5M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$4.81M |
| 5 |
Renaissance Technologies
New York
|
-$4.22M |
IRMD Hedge Fund Activity: Q2 2026 in Review
214 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in iRadimed (IRMD) for Q2 2026, worth a combined $750M — up 2.2% from $734M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of IRMD and 19 opened new positions — a net loss of 11 holders — while 61 trimmed existing stakes and 98 added.
The largest buyer was Arrowstreet Capital, adding an estimated $11.7M. The largest seller was Nine Ten Capital Management, cutting an estimated $7.1M.
- 214 institutional investors held iRadimed (IRMD) as of Q2 2026, down from 228 in Q1 2026.
- Funds reported $750M of iRadimed stock for Q2 2026, up 2.2% quarter-over-quarter.
- 19 funds opened new iRadimed positions in Q2 2026 and 30 closed out, a net change of -11 holders.
- The largest iRadimed buyer in Q2 2026 was Arrowstreet Capital, an estimated $11.7M added.
- The largest iRadimed seller in Q2 2026 was Nine Ten Capital Management, an estimated $7.1M sold.
Based on aggregated 13F filings for Q2 2026.